Can NAD+ Slow Alzheimer's and Parkinson's?
Cells don’t age uniformly. The process is orchestrated — and one of the most important conductors is a molecule called NAD+ (nicotinamide adenine dinucleotide), which cells use to generate energy, repair DNA, and regulate their own maintenance programs. NAD+ levels peak in your twenties and decline steadily from there, and a growing body of research suggests this decline is not just a footnote to aging but one of its core drivers.
In March 2026, Nature Aging published a landmark review bringing together more than 25 scientists from the University of Oslo, Akershus University Hospital, Harvard Medical School, and the Buck Institute for Research on Aging. Their goal: map the current state of NAD+ science as it relates to aging and neurodegenerative disease, and define where the field goes next.
What NAD+ Actually Does Inside Your Cells
NAD+ is often described as a “cellular fuel regulator,” but that undersells its role. It operates across three distinct biological systems simultaneously.
Energy production. Mitochondria — the organelles that convert glucose and fatty acids into ATP, the energy currency cells actually use — require NAD+ as an electron carrier. Without it, the conversion process becomes inefficient. Cells that are energy-hungry, like neurons and skin fibroblasts, feel this first.
DNA repair. Every cell accumulates thousands of DNA lesions daily. An enzyme family called PARP (poly ADP-ribose polymerase) handles emergency repairs, but PARPs consume NAD+ to function. As NAD+ declines with age, repair capacity decreases and damage accumulates faster than it can be corrected.
Cellular maintenance. Sirtuins — a family of proteins often called “longevity regulators” — require NAD+ to do their job. They regulate how quickly cells age, suppress inflammatory signaling, and maintain mitochondrial health. When NAD+ drops, sirtuins become less active across the board.
The Alzheimer and Parkinson Connection
The Nature Aging review gives particular attention to neurodegenerative disease. Alzheimer’s (the progressive loss of memory and cognitive function) and Parkinson’s (the deterioration of dopamine-producing neurons that control movement) share a common cellular profile: mitochondrial dysfunction, elevated oxidative stress (damage from reactive oxygen species), and impaired cellular cleanup.
The review compiled evidence linking declining NAD+ levels to these same patterns in brain tissue. Neurons are especially vulnerable — they are among the most energy-intensive cells in the body, with limited regenerative capacity. A drop in NAD+ hits them harder and earlier than other cell types.
“Fine-tuning NAD+ metabolism is a promising strategy for slowing age-related decline,” said Dr. Jianying Zhang, one of the study’s researchers. Lead author Dr. Evandro Fei Fang described the review as “a scientific roadmap — guiding both future research and clinical application.”
NMN and NR: Where the Supplement Science Stands
NAD+ itself isn’t an effective oral supplement. The molecule is too large to pass efficiently through cell membranes. Instead, precursors — NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) — are converted into NAD+ inside cells after absorption, making them the practical delivery vehicle.
Early clinical trials have shown encouraging signals in memory, physical movement, and metabolic health. The review notes these findings but also flags the limits: most trials to date have been small and short. Optimal dosing, long-term safety profiles, and tissue-specific effects are not yet established.
If you’re considering NMN or NR, the most useful first step isn’t choosing between them — it’s checking your current supplement stack. Multivitamins and B-complexes frequently contain niacin (vitamin B3), which is in the same precursor family. Stacking without knowing what’s already there is the fastest way to reach unintentional high doses.
The Same Mechanism, One Floor Down: Skin Aging
The pathway connecting NAD+ to skin aging isn’t a separate story. Skin fibroblasts — the cells responsible for collagen synthesis — rely on mitochondrial energy production the same way neurons do. When NAD+ levels fall, fibroblast energy output declines, collagen synthesis slows, and the structural support network of the skin thins. The visible result is reduced elasticity and earlier wrinkle formation.
Direct clinical trials on skin aging and NAD+ precursors remain limited, but the cellular mechanism is well-documented. The same biology driving the brain findings operates in the skin. Whether NAD+ supplementation produces measurable cosmetic effects is a question the next generation of trials is beginning to ask.
A Roadmap, Not a Claim
The Nature Aging review is careful about what it asserts. It doesn’t position NAD+ as a solution to Alzheimer’s or Parkinson’s. It positions it as a compelling target — with enough mechanistic and early clinical evidence to warrant serious investigation, and enough open questions to demand more rigorous trials.
Twenty-five researchers from competing institutions agreeing on a shared scientific roadmap is itself a signal. It means the field has matured past hypothesis into structured inquiry. The next phase will fill in the numbers: doses, durations, which tissues respond, and who benefits most.
What is NAD+ and why does it matter? It’s a molecule present in every cell that powers energy production, DNA repair, and cellular maintenance. Levels decline naturally with age, and this decline is linked to memory loss, muscle deterioration, and accelerated aging.
Should I take NMN or NR? Both are precursors your body converts to NAD+. Current evidence doesn’t definitively favor one. Before starting either, check whether your existing supplements already contain niacin (vitamin B3) to avoid inadvertent high-dose stacking.
Does this connect to skin aging? Yes, at the cellular level. The same NAD+-to-mitochondria-to-collagen pathway active in neurons operates in skin fibroblasts. Direct skin clinical trials are limited, but the mechanistic connection is the same.